PTO/SB/08B (07-05)

Approved for use through 07/31/2006. 0MB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/536,628 INFORMATION DISCLOSURE Filing Date Nov/27/2003 STATEMENT BY APPLICANT First Named Inventor HAJ-YEHIA, Abdullah Ibrahim Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number 0-06-227 Sheet 5 4 of

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.		ite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title			
/Y.C./		Amery A. et al.: Lancet 1 (1985) 1349-54			
000000000000000000000000000000000000000	`	Ames B.N. et al.: Proc. Natl. Acad. Sci. USA. 90 (1993) 7915-22			
		Opie L. H.: Drugs for the heart, 5th ed. (2001) pp 107-153			
000000000000000000000000000000000000000		Garison J.C. et al: Cardiovascular Drugs, In: Goodman and Gillman's: The Pharmacological Basis of Therapeutics, Goodman A.G. et al., 8th ed. Pergamon Press, USA. p. 752 (1990)			
***************************************		Ondetti M.A.: Circulation 77 (supp I) (1988) I74-I78			
200000000000000000000000000000000000000		Griendling, K.K. et al.: Circ. Res. 74 (1994) 1141-48; Rajagopalan, S. et al.: J Clin. Invest. 97 (1996) 1916-23			
000000000000000000000000000000000000000		Bartosz M.: Free Radical Biology and Medicine 23 (1997) 729-35; Mak I.T.: Biochem. Pharmacol. 40 (1990) 2169-75			
		Munzel T. J: Clin. Invest. 95 (1995) 187-94			
4 4		Haj-Yehia A. et al.: Drug. Development Res.50 (2000) 528-36			
/Y.C./		Wolf et al., J. Neurosurg. 89 (1998) 279-88			

Examiner /Yong Chu/	Date	07/18/2008
Signature Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				are required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Suosiilui	9 10F10(III (449/F1O			Application Number	10/536,628	
INFO	ORMATION	DIS	CLOSURE	Filing Date	Nov/27/2003	
STA	TEMENT B	Y AI	PPLICANT	First Named Inventor	HAJ-YEHAI, Abdula Ibrahim	
	##	_4		Art Unit	1614	
	(Use as many she	ets as no	ecessary)	Examiner Name		
Sheet	5	of	5	Attorney Docket Number	0-06-227	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/Y.C./	,	Iwanaga Y. et al., The FASEB Journal, vol. 18, March 2004, pages 587-588	
/Y.C./		Rajagopalan, S. et al.: J Clin. Invest. 97 (1996) 1916-23	
/Y.C./	•	Zusman, R.M.: Am. J. Cardiol. 72 (1993) 25H-36H	
		·	
		·	

			<del></del>
Examiner	/Yong Chu/	Date	07/18/2008
Signature	/ Forig Critis	Considered	5.710/2050

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.